eTMF Best Practice for a Lean Team
The TMF is the official record of the clinical study for Regulatory Authorities, be it the FDA, Health Canada, or…
What’s Best for Your Phase III Clinical Study?
It’s worth your time to consider whether or not the commonly held belief that using a larger CRO for your…
Special Report: What’s in Store for Global Clinical Trials in 2022 and Beyond?
The Global Clinical Trials Market was valued at $44.3B USD in 2020, and by 2028 is expected to reach $69.3B…
Prime Location for Global Clinical Studies?
Canada is considered one of the most attractive places to live in the world, with a high quality of life,…
What & Where: the ‘Next Normal’ in Oncology Clinical Research
Developing oncology compounds is a constantly evolving process, and never more so than now. Pre-pandemic oncology was both the largest…
Diversity in Clinical Trial Participants: Canada Holds Promise
Participant diversity in clinical trials can be quite challenging to achieve. With COVID the concern about appropriate demographic representation is…
Overcome Oncology Clinical Trial Obstacles – 2020 Real World Evidence for 2021 and Beyond
Study start-up is one the most time-intensive areas within clinical drug development, accounting for two thirds or more of total…
Looking for Key Clinical Trial Vendor Management Strategies?
Clinical trials, and in particular oncology studies, can be very complex and often involve multiple parties: Sponsor, CRO (sometimes several…
Consider This Region for Your Phase 3 Global Trial
As of May 2020 ClinicalTrials.gov lists 16,150 oncology trials registered as Recruiting, Not yet Recruiting Studies, and the chart below…
Recommendations for Quicker CTA Negotiation
Whether in Canada or any other country it is no secret that executing Clinical Trial Agreements (CTAs) is often the…